Therapy of bone metastases of prostate cancer with Ra-223-dichloride (Xofigo®)
Therapy with Ra-223-dichloride has been introduced in our institution in 2014. A large study has shown that therapy with Ra-223-dichloride can prolong the life of patients with bone metastases of prostate cancer, even in cases when antihormonal treatment and chemotherapy are not effective anymore.
You will receive six injections of Ra-223-dichloride in time intervals of 4 weeks. The therapy can be performed in an outpatient setting. For each injection, you have to plan a 2-3 hour visit to our institution. However, the first appointment might take longer, as you will also receive detailed information about the therapy and we might have to perform additional tests (e.g. bone scintigraphy, laboratory values, PSMA PET/CT). After injection of Ra-223-dichloride, you are allowed to leave our department directly without additional waiting times. For therapy monitoring, bone scans are performed before the 4th injection and 4 weeks after the last injection.
Ra-223-dichoride is indicated in patients with symptomatic bone metastases of prostate cancer who already have received two systemic treatments before (excluding LHRH-analogs). Please consult your treating physician (e.g. urologist or oncologist) about Ra-223-dichloride treatment. You can also contact us directly or make an appointment in our institution (therapy secretary’s office, see contact information below) to check if Ra-223-dichloride is a therapy option for you. An application form for Ra-223-dichloride therapy is also available for download. We will then get in contact with you and/or your treating physicians to plan all necessary further steps.
We want to determine the optimal treatment for each individual patient. Therefore, we will discuss Ra-223-dichloride treatment with your treating physician (e.g. urologist, oncologist). In complex cases, we will also discuss Ra-223-dichloride treatment together with experts of our institution in an interdisciplinary setting (Centre for Integrated Oncology, CIO).
Therapy secretary office / enquiries
Mrs. Oregan Vautey
Tel: +49 (0)228 287 16171
Tel: +49 (0)228 287 16855
Fax: +49 (0)228 287 19107